WO2008109740A3 - Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers - Google Patents

Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers Download PDF

Info

Publication number
WO2008109740A3
WO2008109740A3 PCT/US2008/056035 US2008056035W WO2008109740A3 WO 2008109740 A3 WO2008109740 A3 WO 2008109740A3 US 2008056035 W US2008056035 W US 2008056035W WO 2008109740 A3 WO2008109740 A3 WO 2008109740A3
Authority
WO
WIPO (PCT)
Prior art keywords
neoplasias
cancers
hyper
therapy
prevention
Prior art date
Application number
PCT/US2008/056035
Other languages
French (fr)
Other versions
WO2008109740A2 (en
Inventor
David A Zarling
Hirak S Basu
Balaraman Kalyanaraman
Joy Joseph
Original Assignee
Colby Pharmaceutical Company
Wisconsin Med College Inc
David A Zarling
Hirak S Basu
Balaraman Kalyanaraman
Joy Joseph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colby Pharmaceutical Company, Wisconsin Med College Inc, David A Zarling, Hirak S Basu, Balaraman Kalyanaraman, Joy Joseph filed Critical Colby Pharmaceutical Company
Priority to EP08731532A priority Critical patent/EP2139522A2/en
Publication of WO2008109740A2 publication Critical patent/WO2008109740A2/en
Publication of WO2008109740A3 publication Critical patent/WO2008109740A3/en
Priority to US13/897,801 priority patent/US20130338110A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The inventions disclosed include methods of treating cancers and related neoplasias, especially prostate cancer, with pharmaceutically acceptable salts comprising lipophilic cation moieties linked to nitroxide or linked to hydroxylamine anti-oxidant groups, especially derivatives of TEMPO.
PCT/US2008/056035 2007-03-06 2008-03-06 Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers WO2008109740A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP08731532A EP2139522A2 (en) 2007-03-06 2008-03-06 Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
US13/897,801 US20130338110A1 (en) 2007-03-06 2013-05-20 Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90523707P 2007-03-06 2007-03-06
US60/905,237 2007-03-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/554,476 Continuation US8466130B2 (en) 2007-03-06 2009-09-04 Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers

Publications (2)

Publication Number Publication Date
WO2008109740A2 WO2008109740A2 (en) 2008-09-12
WO2008109740A3 true WO2008109740A3 (en) 2008-11-06

Family

ID=39591290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/056035 WO2008109740A2 (en) 2007-03-06 2008-03-06 Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers

Country Status (2)

Country Link
EP (1) EP2139522A2 (en)
WO (1) WO2008109740A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2011066537A1 (en) * 2009-11-30 2011-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
JP5780497B2 (en) * 2011-03-10 2015-09-16 国立大学法人京都大学 Amphiphilic compound having stable radical structure, surfactant using the amphiphilic compound, micelle using the amphiphilic compound, and emulsion using the amphiphilic compound
US11274114B2 (en) 2014-08-14 2022-03-15 The Medical College Of Wisconsin, Inc. Modified mito-metformin compounds and methods of synthesis and use thereof
US20240109925A1 (en) * 2021-01-26 2024-04-04 The Medical College Of Wisconsin, Inc. Enhanced Anti-Proliferative and Antitumor Immune Effects of Mitochondria-Targeted Hydroxyurea

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053835A1 (en) * 1997-05-27 1998-12-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
WO2000000157A2 (en) * 1998-06-26 2000-01-06 Georgetown University Medical Center Use of tempo and tempo derivatives for inducing cell death
JP2004262823A (en) * 2003-02-28 2004-09-24 Otsuka Chemical Co Ltd Water-soluble n-oxyl compound, oxidation catalyst, and production method of oxide using the catalyst

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053835A1 (en) * 1997-05-27 1998-12-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
WO2000000157A2 (en) * 1998-06-26 2000-01-06 Georgetown University Medical Center Use of tempo and tempo derivatives for inducing cell death
US20040024025A1 (en) * 1998-06-26 2004-02-05 Georgetown University Compositions and methods for inducing cell death
JP2004262823A (en) * 2003-02-28 2004-09-24 Otsuka Chemical Co Ltd Water-soluble n-oxyl compound, oxidation catalyst, and production method of oxide using the catalyst

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHIGNELL, COLIN F. ET AL: "Synthesis of some spin-labeled analogs of drug molecules", JOURNAL OF MEDICINAL CHEMISTRY , 15(8), 876-8 CODEN: JMCMAR; ISSN: 0022-2623, 1972, XP002495511 *
DESSOLIN, JEAN ET AL: "Selective targeting of synthetic antioxidants to mitochondria: towards a mitochondrial medicine for neurodegenerative diseases?", EUROPEAN JOURNAL OF PHARMACOLOGY , 447(2-3), 155-161 CODEN: EJPHAZ; ISSN: 0014-2999, 2002, XP002495510 *
DHANASEKARAN, ANURADHA ET AL: "Mitochondria superoxide dismutase mimetic inhibits peroxide-induced oxidative damage and apoptosis: Role of mitochondrial superoxide", FREE RADICAL BIOLOGY & MEDICINE , 39(5), 567-583 CODEN: FRBMEH; ISSN: 0891-5849, 2005, XP005013087 *
HARTSEL, SCOTT C. ET AL: "Time-dependent binding of paramagnetic and fluorescent hydrophobic ions to the acetylcholine receptor from Torpedo", BIOCHEMISTRY , 26(12), 3253-60 CODEN: BICHAW; ISSN: 0006-2960, 1987, XP002495508 *
ISHII K ET AL: "In vitro photodynamic effects of phthalocyaninatosilicon covalently linked to 2,2,6,6-tetramethyl-1-piperidinyloxy radicals on cancer cells", FREE RADICAL BIOLOGY AND MEDICINE, ELSEVIER SCIENCE, vol. 38, no. 7, 1 April 2005 (2005-04-01), pages 920 - 927, XP004776294, ISSN: 0891-5849 *
KUBOTA, JUN ET AL: "Water-soluble N-oxyl compounds-mediated electrooxidation of alcohols in water: a prominent access to a totally closed system", TETRAHEDRON LETTERS , 46(52), 8975-8979 CODEN: TELEAY; ISSN: 0040-4039, 2005, XP005181351 *
See also references of EP2139522A2 *

Also Published As

Publication number Publication date
EP2139522A2 (en) 2010-01-06
WO2008109740A2 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
WO2008027445A3 (en) Combination with bis(thiohydrazide amides) for treating cancer
PT2139483E (en) Combination therapies comprising a quinoxaline inhibitor of pi3k-alpha for use in the treatment of cancer
BRPI0814542A2 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND TUMOR-RELATED DISORDERS
NO20091661L (en) Use of pegylated IL-10 to treat cancer
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
MX2009008132A (en) Combination therapy with angiogenesis inhibitors.
HK1120441A1 (en) Drugs for treatment of ovarian cancer
WO2009011850A3 (en) Novel therapeutic compounds
EA201100971A1 (en) DERIVATIVES OF PYRIMIDININDOL FOR THE TREATMENT OF MALIGNANT NORMALIZATION
WO2010056919A3 (en) Eflornithine prodrugs, conjugates and salts, and methods of use thereof
WO2007050784A3 (en) Fixed ratio drug combination treatments for solid tumors
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
WO2009012096A3 (en) Improved therapeutic methods and compositions comprising chroman ring compounds
ZA200907245B (en) Phthalazinone derivatives and their use as medicament to treat cancer
IL200410A0 (en) Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
ZA201005116B (en) 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders
WO2014194030A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
EP2224919A4 (en) Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
WO2008109740A3 (en) Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
ATE458487T1 (en) TUMOR TREATMENT WITH GLIOTOXIN DERIVATIVES
WO2010151074A3 (en) Photosensitizer containing conjugates of quantum dot-chlorine derivatives and composition for treating and diagnosing cancer containing same for photodynamic therapy
WO2009105217A3 (en) Complement inhibitors as therapeutic agents for treatment of cancer
MX2010003269A (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase.
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731532

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008731532

Country of ref document: EP